International Psoriasis Council
Advancing Knowledge. Enhancing Care.
COVID-19 Commentaries
Read the views of IPC’s global experts regarding COVID-19 and psoriasis management.
Errol Prens, MD, PhD
Erasmus University Medical Center
Rotterdam, Netherlands
MAY 17, 2022
Publication
Sex differences in immune responses that underlie COVID-19 disease outcomes. Takahashi T, Ellingson MK, Wong P. Nature. 2020 Dec; 588(7837):315-320. doi: 10.1038/s41586-020-2700-3. Epub 2020 Aug 26. PMID: 32846427; PMCID: PMC7725931.
Arnon Cohen, MD, MPH, PhD
Clalit Health Services
Tel Aviv, Israel
JANUARY 26, 2022
Publication
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Satveer K Mahil, Katie Bechman, Antony Raharja, et al. Lancet Rheumatol. 2022; Vol 4:e42–52.https://doi.org/10.1016/S2665-9913(21)00333-7.
Luigi Naldi, MD
Centro Studi GISED
Bergamo, Italy
July 7, 2021
Publication
Lars Iversen, MD, DMSc
Aarhus University Hospital
Aarhus, Denmark
IPC Board Member
MAY 25, 2021
Publication
Psoriasis. Griffiths C, Armstrong A, Gudjonsson J, Barker J. Lancet. vol. 397. no. 10281. 2021 Apr; 397: 1301–15. doi: 10.1016/s0140-6736(20)32549-6.
Francesca Capon, MD
Guy’s Hospital
London, England, United Kingdom
FEBRUARY 8, 2021
Publication
Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. Patrick M, Zhang H, Wasikowski R, et al. J Allergy Clin Immunol. 2021 Jan 21 doi: 10.1016/j.jaci.2021.01.006 [Epub ahead of print]
Johann Gudjonsson, MD, PhD
University of Michigan
Ann Arbor, Michigan, United States
IPC Board Member
FEBRUARY 2, 2021
Publication
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have a low prevalence of SARS-CoV-2 seroconversion. Simon D, Tascilar K, Krönke G, et al. Nat Commun. 2020 Jul 24;11(1):3774. doi: 10.1038/s41467-020-17703-6. PMID: 32709909; PMCID: PMC7382482.
Department of Dermatology, Hôpital Saint-Louis, Imagine Institute for Human Genetic Diseases, University of Paris
Paris, France
IPC Vice President/President Elect
Publication
Jörg Prinz, MD
Ludwig Maximilians University
Munich, Germany
OCTOBER 23, 2020
Publication
Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study. Mahil S, Dand N, Mason KJ, et al. J Allergy Clin Immunol. 2020 Oct 16; S0091-6749(20)31413-5. doi: 10.1016/j.jaci.2020.10.007. [Epub ahead of print]
Alan Menter, MD
Texas Dermatology Associates
Dallas, Texas, United States
Honorary Founder
Ulrich Mrowietz, MD
University Medical Center Schleswig-Holstein
Kiel, Germany
OCTOBER 6, 2020
Publication
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. Gelfand J, Armstrong A, Bell S, et al. (2020). Journal Of The American Academy Of Dermatology. doi: 10.1016/j.jaad.2020.09.001
Marcus Schmitt-Egenolf, MD, PhD
Umea University
Umea, Sweden
AUGUST 20, 2020
Publication
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Mahil SK, Wilson N, Dand N, et al. Br J Dermatol. 2020 May;182(5):1158-1166.
Tiago Torres, MD, PhD
Abel Salazar Institute of Biomedical Sciences,
Porto, Portugal
AUGUST 13, 2020
Publication
OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Williamson EJ, Walker AJ, Bhaskaran K, et al. Nature. 2020 Jul 8. doi: 10.1038/s41586-020-2521-4.
Jo Lambert, MD, PhD
Ghent University Hospital
Ghent, Belgium
JULY 22, 2020
Publication
Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice. Gisondi P, Piaserico S, Conti A, Naldi L. JEADV, 2020, 34: 1196-1201.
April Armstrong, MD, MPH
Keck School of Medicine, USC
Studio City, California, United States
JULY 22, 2020
Publication
Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during Covid-19 emergency in a tertiary center in Italy [published online ahead of print, 2020 May 26]. Brunasso AMG, Massone C. Dermatol Ther. 2020;e13495. doi:10.1111/dth.13695.
Luigi Naldi, MD
Centro Studi GISED
Bergamo, Italy
May 28, 2020
Publication
The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic. Wan MT, Shin DB, Winthrop KL, Gelfand JM. Journal of the American Academy of Dermatology (2020), doi: https://doi.org/10.1016/j.jaad.2020.05.035.
Lluís Puig, MD, PhD
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
IPC Board Member
Publication
Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases. Galván Casas C, Català A, Carretero Hernández G, et al. BJD. First published:29 April 2020. https://doi.org/10.1111/bjd.19163
Ulrich Mrowietz, MD
University Medical Center Schleswig-Holstein
Kiel, Germany
MAY 14, 2020
Publication
COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Schett G, Sticherling M, Neurath MF. Nat Rev Immunol. 2020;20(5):271‐272. doi:10.1038/s41577-020-0312-7
Mark Lebwohl, MD
Mt Sinai
New York, New York, United States
MAY 12, 2020
Publication
Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York. A. Chen, R. Castillo, S. Adhikari, D. Hudesma. Letter to the editor. NEJM. April 29, 2020. DOI: 10.1056/NEJMc2009567
Peter van de Kerkhof, MD, PhD, Chief Medical Officer
International Psoriasis Council
Amsterdam, Netherlands
MAY 1, 2020
Publication
Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment. Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G, R. Journal of the American Academy of Dermatology (2020), DOI: https://doi.org/10.1016/ j.jaad.2020.04.085.
Disclaimer: Views expressed in this commentary are those of the authors and do not necessarily represent the position of the International Psoriasis Council or its Board of Directors.